Meta-analysis compares EGFR inhibitors versus bevacizumab for converting unresectable liver metastases

▸ TREATMENT

A systematic review and meta-analysis of randomized trials in patients with RAS wild-type colorectal liver metastases compared chemotherapy combined with EGFR inhibitors versus bevacizumab as first-line treatment, analyzing data from 795 patients across six randomized controlled trials. (Critical Reviews in Oncology/Hematology)